Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD
Clicks: 1
ID: 318919
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #94 of 98 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background and Hypothesis Finerenone reduces cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The cardiovascular benefit emerges within months, before measurable kidney protection, but the early pathways carrying it are not comprehensively quantified. We hypothesized that early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure (SBP) jointly mediate a substantial proportion of finerenone’s long-term cardiovascular benefit, whereas changes in body weight and serum potassium do not. Methods We performed causal mediation analysis using individual patient data from FIDELITY (pooled FIDELIO-DKD and FIGARO-DKD; n = 12,143). Mediators were change from baseline to month 4 in log urine albumin-to-creatinine ratio (UACR), systolic blood pressure (SBP), body weight, and serum potassium. The outcome was time from month 4 to first cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization). Outcome models used parametric accelerated failure time regression with Weibull distribution. Joint mediation by UACR and SBP was estimated by bootstrapping. Results At month 4, finerenone reduced UACR by 32.2% (95% CI 30.3 to 34.2), SBP by 3.6 mmHg (3.1 to 4.1), and body weight by 0.23 kg (0.13 to 0.32), and increased serum potassium by 0.19 mEq/L (0.17 to 0.20). Although all four biomarkers changed significantly, only UACR and SBP mediated cardiovascular outcomes: UACR mediated 39% (95% CI 7 to 71) and SBP mediated 21% (3 to 40); body weight and potassium did not. Jointly, UACR and SBP mediated 50% (95% CI 21 to 100) of the cardiovascular benefit. Conclusions In T2D and CKD, early reductions in UACR and SBP jointly account for half of finerenone’s long-term cardiovascular benefit. Body weight and potassium changes do not mediate the benefit, supporting UACR and SBP as complementary indicators of cardiovascular efficacy.
| Reference Key |
openalex_W7166015679
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Rajiv Agarwal, Ambarish Pandey, Scott D. Solomon, Muthiah Vaduganathan, Faı̈ez Zannad |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag150
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.